Amicretina: New Medicine promises to lose more than Ozepic and Mounjaro

Nuovo Nordisk successfully completed a clinical study with a subcutaneous friend, a new promising drug in the treatment of obesity and overweight. The first results indicate the effectiveness and safety in treatment with this substance which is the junction of two hormones: LPG -1 – produced mainly by intestinal cells – and Amilina, produced in the pancreas, responsible for the feeling of satiety.

The “The Lancet” scientific magazine has published new results that underline that Amicrettine can cause a reduction of more than 24% of the body weight for a period of 36 weeks.

“He acts in thermogenesis, in the loss of fat, increasing satiety”, explained the medical nutritionist Stella Cardoso, in a video published on his social networks.

In studies, the substance has overcome the results compared to Ozepic, Wegovy and Tizerpatida – which is Mounjaro.

“We are very enthusiastic about the results of the subcutaneous phase of Amicretina 1b/2a in overweight or obesity people,” said Martin Lange, executive vice -president for the development of Novo Nordisk, the same company that produces Ozimpic and Wegovy, for obesity.

“The results observed in the test support the weight reduction potential of this new unimolecular agonist of the LPG-1 and Amilina receptors, which we have previously seen with the oral formulation,” he added.

The pharmacist responsible for the new drug has also shown that the subcutaneous weekly treatment with dose reduction of up to 60 mg “was well tolerated and with a safety profile similar to other agonists of the LPG-1 and Amilina receptors”.

It is important to underline that the drug is still under study and should still take time to be marketed.

Source: Terra

Ben

Ben Stock is a lifestyle journalist and author at Gossipify. He writes about topics such as health, wellness, travel, food and home decor. He provides practical advice and inspiration to improve well-being, keeps readers up to date with latest lifestyle news and trends, known for his engaging writing style, in-depth analysis and unique perspectives.